Methods for administering long-lasting hypoglycemic agents
The present invention relates to methods and pharmaceutical compositions relating to administering hypoglycemic agents and/or GLP-1 agonists wherein the mean maximum plasma concentration (Cmax) and/or Area Under the Curve (AUC) values of the hypoglycemic agent are increased and/or sustained.
1. A method for enhancing GLP-1 activity in a human, which method comprises subcutaneously administering to said human a composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1, providing a maximum plasma concentration of said polypeptide of at least about 0.6 nM and providing an Area Under the Curve value of said polypeptide which is at least about 3.5 nM×day over the period of one week wherein said composition is administered to said human at a time interval selected from: once every week, once every fourteen days, once every four weeks and once a month.
2. The method of claim 1 , wherein said composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 is administered to said human once a week.
3. The method of claim 1 , wherein said composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 comprises about 0.25 mg to about 104 mg of said polypeptide.
4. The method of claim 1 , further comprising providing a maximum plasma concentration of at least about 0.6 nM to about 319 nM of the polypeptide having the amino acid sequence of SEQ ID NO:1 and an Area Under the Curve value of said polypeptide of at least about 3.5 nM×day to about 1936 nM×day over the period of one week.
5. The method of claim 1 , further comprising providing a maximum plasma concentration of at least about 8 nM to about 54 nM of the polypeptide having the amino acid sequence of SEQ ID NO:1 and providing AUC (Week 1) value of said polypeptide of at least about 29 nM×day to about 245 nM×day over the period of one week wherein said composition comprises about 16 mg to about 64 mg of said polypeptide.
6. The method of claim 1 , further comprising providing a serum half life of the polypeptide having the amino acid sequence of SEQ ID NO:1 of about 4 days to about 7 days.
7. The method of claim 1 , further comprising providing a Tmax value of the polypeptide having the amino acid sequence of SEQ ID NO:1 of about 1 day to about 5 days.
8. The method of claim 1 , wherein said human has hyperglycemia.
9. The method of claim 1 , wherein said human has diabetes.
10. The method of claim 1 , wherein said human has type II diabetes mellitus.
11. The method of claim 10 , further comprising administering said composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 subcutaneously in the leg, arm, or abdomen of said human.
12. A method for treating Type II diabetes in a human comprising subcutaneously administering to said human a pharmaceutical composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 and providing a maximum plasma concentration of at least about 8 nM to about 54 nM of said polypeptide and providing an AUC (0-∞) value of said polypeptide after a single dose of at least about 99 nM×day to about 637 nM×day wherein said composition is administered to said human at a time interval selected from: once every week, once every fourteen days, once every four weeks and once a month and wherein said composition comprises about 16 mg to about 64 mg of said polypeptide.
13. The method of claim 12 wherein said composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 further comprises mannitol, trehalose dihydrate, polysorbate 80, and phosphate buffer.
14. The method of claim 12 further comprising formulating the polypeptide having the amino acid sequence of SEQ ID NO:1 as 25 mg/mL.
15. The method of claim 12 further comprising subcutaneously administering said polypeptide having the amino acid sequence of SEQ ID NO:1 at a dose of about 24 mg to about 60 mg.